Dermatologists and the AMA are opposing a TGA proposal to down-schedule topical mometasone products (0.1% or less in packs of 15g or less) from a Schedule 4 to a Schedule 3 drug. In a submission to the TGA Advisory Committee on Medicines Scheduling (ACMS), the AMA said dermatologist and GP members were unanimous that the ...
Dermatologists oppose OTC mometasone for topical use
By Mardi Chapman
7 Feb 2019